Daniel Ortega is Vice President of Development and Technical Operations at Plus Therapeutics, Inc. He is responsible for end-to-end drug development, GMP manufacturing, clinical supply chain management, and CMC oversight across the company’s radiotherapeutic portfolio.
Mr. Ortega brings nearly 20 years of pharmaceutical industry experience, including technical and leadership roles at Azaya Therapeutics, Mission Pharmacal, and Viatris (formerly DPT Laboratories). His expertise includes leading GMP manufacturing, regulatory-aligned CMC execution, and complex technology transfers across small molecule, nanomedicine, and radiopharmaceutical platforms, with a focus on clinical development and commercial readiness.
Mr. Ortega holds a Bachelor of Science from the University of Texas at San Antonio and an MBA from Texas A&M University–San Antonio.